Phentolamine Mesylate Ophthalmic Solution Provides Lasting Pupil Modulation and Improves Near Visual Acuity in Presbyopic Glaucoma Patients in a Randomized Phase 2b Clinical Trial

Jay S. Pepose, Paul J. Hartman, Harvey Dubiner, Marc Abrams, Robert Smyth-Medina, Sayoko E. Moroi, Alan Meyer, Mina Sooch, Reda Jaber, Konstantinos Charizanis, Seth A. Klapman, Arin T. Amin, Jonah Yousif, Eliot Lazar, Paul Karpecki, Charles B. Slonim, Marguerite B. McDonaldClinical 2021 · DOI

Abstract

Although mean IOP was not lowered significantly, daily evening dosing of 1% PMOS was found to be well tolerated with no daytime conjunctival redness and demonstrated improvement in DCNVA with sustained PD reduction in a glaucomatous and presbyopic population. Smaller pupil size can have beneficial effects in improving symptoms of presbyopia and DLD, which will be the focus of further studies.
BibTeX
@inproceedings{pepose2021phentolamine,
  author = {Jay S. Pepose and Paul J. Hartman and Harvey Dubiner and Marc Abrams and Robert Smyth-Medina and Sayoko E. Moroi and Alan Meyer and Mina Sooch and Reda Jaber and Konstantinos Charizanis and Seth A. Klapman and Arin T. Amin and Jonah Yousif and Eliot Lazar and Paul Karpecki and Charles B. Slonim and Marguerite B. McDonald},
  title = {{Phentolamine Mesylate Ophthalmic Solution Provides Lasting Pupil Modulation and Improves Near Visual Acuity in Presbyopic Glaucoma Patients in a Randomized Phase 2b Clinical Trial}},
  booktitle = {Clinical},
  year = {2021},
  doi = {10.2147/opth.s278169},
}

Loading related content...

Figure